ESLAWEstrella Immunopharma Inc. Warrant
0.0750USD+11.03%Mkt Cap: —P/E: —8d ago
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the t…
Industry Peers
Biotechnology$137.30BUSDP/E 31.5
$81.77BUSDP/E 19.7
$63.63BUSDP/E 38.9
$59.19BUSDP/E 38.8
$55.09BUSD
$44.62BUSDP/E 19.0
$44.56BUSD
$41.49BUSDP/E 65.6
$35.16BUSDP/E 32.7
$31.73BUSDP/E 41.2
$25.89BUSD
$25.64BUSD
$25.21BUSDP/E 15.8
$25.07BUSD
$19.27BUSDP/E 26.2
$20.42BUSDP/E 26.2
$16.26BUSDP/E 19.0
$15.87BUSDP/E 16.7
$14.97BUSD
$13.49BUSDP/E 17.1
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.06M $
Revenue/Share—
Last Price0.0750 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.03
EPS (TTM)—
EPS (Forward)—
52W Range
0.061017% of range0.1424
52W High0.1424 USD
52W Low0.0610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE126.02%
ROA-411.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.79M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-2.46M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.28
Quick Ratio0.25
Book Value/Sh-2.8900 USD
Cash/Share0.0700 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float9.10M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta-0.09
S&P 52W Chg20.20%
Avg Vol (30d)3.12K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—